Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:BLTE News 11 December 2025 - 30 December 2025

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

NEW YORK, December 30, 2025, 05:26 ET — Premarket Belite Bio’s U.S.-listed shares were back in focus early Tuesday after the stock surged 6.7% in the prior session, swinging between $151.50 and $169.75 before ending at $165.29. Volume was 309,235 shares, above recent daily levels for the thinly traded biotech. StockAnalysis The move matters because Belite is trying to turn a rare-disease eye drug into a first-in-class launch, and the stock is now trading well above the $154 level at which it last sold new shares in a major December offering. In markets where liquidity thins out near year-end, sharp
30 December 2025
··
Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio, Inc. (NASDAQ: BLTE) has turned into one of 2025’s most closely watched biotech stories. On the back of a pivotal Phase 3 win in Stargardt disease and a large equity raise, the small-cap ophthalmology specialist has seen its share price more than double this year and its market value climb into the multi‑billion‑dollar range.BioPharma Dive+1 As of the afternoon of December 11, 2025, Belite Bio stock is trading around $154 per share, up roughly 4–5% on the day and more than 130% year‑to‑date, giving the company a market capitalization of roughly $5–6 billion.Stock Titan+1 The rally has pushed
11 December 2025
·

Stock Market Today

Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

7 February 2026
New York, Feb 7, 2026, 11:18 EST — Market closed. Mastercard Incorporated shares (MA.N) last traded down 0.6% at $548.74 on Friday, after moving between $539.90 and $556.65. The stock is about 4% below its 52-week high, according to market data. That small drop still matters because payments names like Mastercard often trade as a clean read on consumer and travel spending. Heading into the new week, the focus shifts back to U.S. growth and rate expectations, which can move the group even when company news is thin. Friday’s tape was not thin. The Dow surged 2.47% to end above
Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop